KIT‐mutated pediatric core‐binding factor systemic mastocytosis‐acute myeloid leukemia treated with avapritinib and decitabine

Pediatric Blood & CancerVolume 71, Issue 4 e30898 LETTER TO THE EDITOR KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine Irtiza N. Sheikh, Irtiza N. Sheikh orcid.org/0000-0003-4869-8818 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorShaikha AlQahtani, Shaikha AlQahtani orcid.org/0009-0004-1176-8952 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorC. Cameron Yin, C. Cameron Yin Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorDavid McCall, David McCall orcid.org/0000-0003-2297-9670 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorBranko Cuglievan, Branko Cuglievan Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorDristhi Ragoonanan, Dristhi Ragoonanan orcid.org/0000-0002-8199-9404 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorJeremy S. Connors, Jeremy S. Connors Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorAmber Gibson, Amber Gibson orcid.org/0000-0002-9146-4702 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorCesar Nunez, Cesar Nunez Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorMichael Roth, Michael Roth orcid.org/0000-0002-6411-8353 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorMaro Ohanian, Maro Ohanian Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorGautam Borthakur, Gautam Borthakur Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorMiriam B. Garcia, Corresponding Author Miriam B. Garcia [email protected] orcid.org/0000-0002-2978-2267 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence Miriam B. Garcia, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030, USA. Email: [email protected]Search for more papers by this author Irtiza N. Sheikh, Irtiza N. Sheikh orcid.org/0000-0003-4869-8818 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorShaikha AlQahtani, Shaikha AlQahtani orcid.org/0009-0004-1176-8952 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorC. Cameron Yin, C. Cameron Yin Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorDavid McCall, David McCall orcid.org/0000-0003-2297-9670 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorBranko Cuglievan, Branko Cuglievan Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorDristhi Ragoonanan, Dristhi Ragoonanan orcid.org/0000-0002-8199-9404 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorJeremy S. Connors, Jeremy S. Connors Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorAmber Gibson, Amber Gibson orcid.org/0000-0002-9146-4702 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorCesar Nunez, Cesar Nunez Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorMichael Roth, Michael Roth orcid.org/0000-0002-6411-8353 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorMaro Ohanian, Maro Ohanian Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorGautam Borthakur, Gautam Borthakur Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorMiriam B. Garcia, Corresponding Author Miriam B. Garcia [email protected] orcid.org/0000-0002-2978-2267 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence Miriam B. Garcia, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 87, Houston, TX 77030, USA. Email: [email protected]Search for more papers by this author First published: 30 January 2024 https://doi.org/10.1002/pbc.30898 Abstract was submitted for publication to the American Society of Pediatric Hematology/Oncology Conference, April 2024, Seattle, Washington. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1Gogia A, Sharawat SK, Kumar R, Sarkar C, Bakhshi S. Systemic mastocytosis associated with childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2013; 35(2): 163-164. doi:10.1097/MPH.0b013e318253f060 10.1097/MPH.0b013e318253f060 PubMedWeb of Science®Google Scholar 2Mahadeo KM, Wolgast L, McMahon C, Cole PD. Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia. Pediatr Blood Cancer. 2011; 57(4): 684-687. doi:10.1002/pbc.23026 10.1002/pbc.23026 PubMedWeb of Science®Google Scholar 3Pullarkat ST, Pullarkat V, Kroft SH, et al. Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. J Hematop. 2009; 2(1): 27-33. doi:10.1007/s12308-009-0023-2 10.1007/s12308-009-0023-2 PubMedGoogle Scholar 4Jawhar M, Kreil S, Schwaab J, et al. Systemic mastocytosis with associated acute myeloid leukemia (SM-AML): a poor-risk multi-mutated disease that follows a distinct diagnostic algorithm and requires high-dose stem cell-targeting therapy. Blood. 2017; 130(1): 2916-2916. doi:10.1182/blood.V130.Suppl_1.2916.2916 10.1182/blood.V130.Suppl_1.2916.2916 Google Scholar 5Qiu K-y, Liao X-y, Li Y, et al. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16). BMC Cancer. 2023; 23(1): 476. doi:10.1186/s12885-023-10965-5 10.1186/s12885-023-10965-5 CASPubMedWeb of Science®Google Scholar 6Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010; 115(12): 2372-2379. doi:10.1182/blood-2009-09-241075 10.1182/blood-2009-09-241075 CASPubMedWeb of Science®Google Scholar 7Srinivasan S, Dhamne C, Patkar N, et al. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1. Pediatr Blood Cancer. 2024; 71(2):e30791. doi:10.1002/pbc.30791 10.1002/pbc.30791 CASPubMedGoogle Scholar 8Yui S, Kurosawa S, Yamaguchi H, et al. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations. Ann Hematol. 2017; 96(10): 1641-1652. doi:10.1007/s00277-017-3074-y 10.1007/s00277-017-3074-y CASPubMedWeb of Science®Google Scholar 9Kim HJ, Ahn HK, Jung CW, et al. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. Ann Hematol. 2013; 92(2): 163-171. doi:10.1007/s00277-012-1580-5 10.1007/s00277-012-1580-5 CASPubMedWeb of Science®Google Scholar 10Solh M, Yohe S, Weisdorf D, Ustun C. Core-binding factor acute myeloid leukemia: heterogeneity, monitoring, and therapy. Am J Hematol. 2014; 89(12): 1121-1131. doi:10.1002/ajh.23821 10.1002/ajh.23821 PubMedWeb of Science®Google Scholar 11Sperr WR, Drach J, Hauswirth AW, et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res. 2005; 11(19): 6787-6792. doi:10.1158/1078-0432.Ccr-05-1064 10.1158/1078-0432.CCR-05-1064 CASPubMedWeb of Science®Google Scholar 12Pullarkat V, Bedell V, Kim Y, et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res. 2007; 31(2): 261-265. doi:10.1016/j.leukres.2006.03.006 10.1016/j.leukres.2006.03.006 CASPubMedWeb of Science®Google Scholar 13Johnson RC, Savage NM, Chiang T, et al. Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013; 140(4): 525-535. doi:10.1309/ajcp1q0ysxeahnkk 10.1309/AJCP1Q0YSXEAHNKK PubMedWeb of Science®Google Scholar 14Popat UR, Mehta RS, Bassett R, et al. Myeloablative fractionated busulfan conditioning regimen with venetoclax in patients with AML/MDS: prospective phase II clinical trial. Blood. 2021; 138: 2879. doi:10.1182/blood-2021-146253 10.1182/blood-2021-146253 Web of Science®Google Scholar 15Tarlock K, Alonzo TA, Wang YC, et al. Functional properties of KIT mutations are associated with differential clinical outcomes and response to targeted therapeutics in CBF acute myeloid leukemia. Clin Cancer Res. 2019; 25(16): 5038-5048. doi:10.1158/1078-0432.Ccr-18-1897 10.1158/1078-0432.CCR-18-1897 PubMedWeb of Science®Google Scholar 16Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012; 30(21): 2670-2677. doi:10.1200/jco.2011.38.9429 10.1200/JCO.2011.38.9429 CASPubMedWeb of Science®Google Scholar 17DeAngelo DJ, Radia DH, George TI, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021; 27(12): 2183-2191. doi:10.1038/s41591-021-01538-9 10.1038/s41591-021-01538-9 CASPubMedWeb of Science®Google Scholar 18 FDA approves avapritinib for advanced systemic mastocytosis. FDA; 2021. Accessed August 29, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-advanced-systemic-mastocytosis Google Scholar Volume71, Issue4April 2024e30898 ReferencesRelatedInformation